COGNITRAC 60MG INJECTION contains Cerebroprotein Hydrolysate which belongs to group of medicines called Neurotrophic agents. It is used to manage cranial injury, aprosexia (inability to concentrate) in dementia, cerebrovascular disease that includes stroke, and Alzheimer's disease.
A cranial injury is a head injury causing trauma to the scalp, skull, or brain. It is characterised by symptoms such as leakage of blood outside the blood vessels, uncontrolled bleeding, skull fracture, brain injury, or swelling in the brain.
A stroke occurs when the blood supply to the brain or part of it is blocked. It is characterised by symptoms such as troubled speech, numbness in the body, visual disturbances, headaches, and troubled waking.
Dementia is a group of symptoms such as loss of memory and thinking/reasoning abilities. Alzheimer’s disease is a disorder that causes progressive degeneration of brain cells, resulting in brain shrinkage. It is characterised by dementia, social withdrawal, and wandering.
COGNITRAC 60MG INJECTION is not recommended for use in patients with severe renal dysfunction, status epilepticus (a life-threatening neurological disorder), or major epilepsia (a seizure that causes loss of consciousness and violent muscle contractions).
COGNITRAC 60MG INJECTION should be used with caution in patients with epilepsy (fits or seizures) and or allergic diathesis (condition causing predisposition to develop group of allergies such as hay fever, allergic rhinitis, bronchial asthma, or atopic dermatitis).
COGNITRAC 60MG INJECTION should be used with caution in pregnant and breastfeeding females only if it is clearly needed. COGNITRAC 60MG INJECTION should be used with caution in elderly patients (above 65 years). Consult your doctor before receiving it.
The common side effects associated with the use of COGNITRAC 60MG INJECTION are headache, nausea, vertigo (sensation of spinning), increased sweating, agitation, fever, and hallucinations. Consult your doctor...
No content available
